Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus.
about
Nonoccupational postexposure prophylaxis following sexual assault in industrialized low-HIV-prevalence countries: A reviewPractical guidance for nonoccupational postexposure prophylaxis to prevent HIV infection: an editorial reviewNew Biomedical Technologies and Strategies for Prevention of HIV and Other Sexually Transmitted InfectionsNon-occupational post-exposure prophylaxis for HIV: 10-year retrospective analysis in Seattle, Washington.Availability of HIV postexposure prophylaxis services in Los Angeles CountyUptake and repeat use of postexposure prophylaxis in a community-based clinic in Los Angeles, California.A randomized noninferiority trial of standard versus enhanced risk reduction and adherence counseling for individuals receiving post-exposure prophylaxis following sexual exposures to HIVSustainability of an HIV PEP Program for Sexual Assault Survivors: "Lessons Learned" from Health Care Providers.Testing the waters: Ethical considerations for including PrEP in a phase IIb HIV vaccine efficacy trial.Optimizing adherence to preexposure and postexposure prophylaxis: the need for an integrated biobehavioral approach.Sexual assault injuries and increased risk of HIV transmission.A systematic review of cost-utility analyses in HIV/AIDS: implications for public policy.HIV-Negative Partnered Men's Willingness to Use Non-Occupational Post-Exposure Prophylaxis and Associated Factors in a U.S. Sample of HIV-Negative and HIV-Discordant Male Couples.Attitudes toward Web application supporting pharmacist-clinician comanagement of postexposure prophylaxis patients.Post-exposure prophylaxis for HIV infection.UK guideline for the use of HIV Post-Exposure Prophylaxis Following Sexual Exposure, 2015.Evaluating counseling outcome on adherence to prophylaxis and follow-up after sexual HIV-risk exposure: a randomized controlled trial.Cost-effectiveness of interventions to prevent HIV and STDs among women: a randomized controlled trial.Expert consensus statement on the science of HIV in the context of criminal law
P2860
Q22248015-FD24D1C5-B59C-45A9-86D5-C48D55358BCDQ26853055-A62898B9-6C7B-45D1-9E63-466101D8A30CQ28072213-29CC261D-562D-4524-BC88-B6B54BDE5537Q34070706-E3481FE5-468F-4DEB-A5AD-2B180DFFD051Q34071050-EE03D782-53BD-468C-B496-E9B3F4DFD9F4Q34116802-1386BA71-184F-4593-8B47-E9D411FF690CQ35031691-832BCA38-0F1C-4FE3-A229-A84F8C1E3BB5Q35645955-A115B03F-1A78-49B5-94D9-BE7FF938D852Q35862766-A3B56503-9679-420A-B0B6-C2858F1BFD85Q35999949-03D9C6A1-323C-41D2-ADD3-9C134D274752Q36467148-1A0CB92D-06E0-4B00-94D3-0CEF0D294BACQ37023469-98CBC2E8-CB12-4BB3-A501-B62236D0C1C5Q37195635-3832D325-7B47-4CD4-9FD0-09E9D839C473Q37507747-3ECB6450-5AF3-4C75-8DE4-63AA909A4A61Q37866814-EEF750EF-0267-4519-B515-BF975A4E0978Q38812601-454CDB1C-3B09-4EB0-A77C-82A8B0D277E4Q43614773-7238241F-7863-40B2-8324-DA2DD7E8B070Q44310198-B7716205-36CA-43F9-A64C-88DC6835784FQ56911620-0C1B46CB-5EEE-4833-ACBB-2891B60AE837
P2860
Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Cost-effectiveness of postexpo ...... human immunodeficiency virus.
@en
Cost-effectiveness of postexpo ...... human immunodeficiency virus.
@nl
type
label
Cost-effectiveness of postexpo ...... human immunodeficiency virus.
@en
Cost-effectiveness of postexpo ...... human immunodeficiency virus.
@nl
prefLabel
Cost-effectiveness of postexpo ...... human immunodeficiency virus.
@en
Cost-effectiveness of postexpo ...... human immunodeficiency virus.
@nl
P2093
P1476
Cost-effectiveness of postexpo ...... human immunodeficiency virus.
@en
P2093
James O Kahn
Jeffrey N Martin
Michelle E Roland
Mitchell H Katz
Steven D Pinkerton
Thomas J Coates
P356
10.1001/ARCHINTE.164.1.46
P407
P577
2004-01-01T00:00:00Z